Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06412471
PHASE2

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

This study includes two parts, part A is for non-squamous NSCLC and part B is for squamous NSCLC.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

235

Start Date

2024-07-26

Completion Date

2025-08

Last Updated

2024-07-30

Healthy Volunteers

No

Interventions

DRUG

SSGJ-707

bispecific antibody

DRUG

carboplatin

chemotherapy

DRUG

Pemetrexed

chemotherapy

DRUG

paclitaxel

chemotherapy

DRUG

PD-1/L1

Immune checkpoint inhibitors

DRUG

Paclitaxel-albumin

chemotherapy

Locations (1)

Institute of The Hunan Cancer Hospital

Changsha, China